
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Although the Epstein-Barr virus causes most illnesses presenting as mononucleosis, clinicians should be able to recognize and consider alternate differential possibilities.






